Reclast is a once-yearly intravenous infusion used to treat osteoporosis and other bone conditions. It contains zoledronic acid, a powerful bisphosphonate that slows bone loss by targeting the cells responsible for breaking down bone. The infusion itself takes about 15 minutes through a vein in your arm, and for most people, that single session provides a full year of protection against fractures.
What Reclast Treats
Reclast is FDA-approved for several bone-related conditions: treatment and prevention of osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, treatment and prevention of osteoporosis caused by long-term steroid use, and treatment of Paget’s disease of bone. Current UK clinical guidelines from 2024 position it alongside oral bisphosphonates as a first-line, cost-effective treatment for osteoporosis. It’s also specifically recommended as a first-line option after a hip fracture.
How It Strengthens Bone
Your bones are constantly being remodeled. Specialized cells called osteoclasts break down old bone, while other cells rebuild it. In osteoporosis, the breakdown outpaces the rebuilding, leaving bones weaker and more prone to fractures.
Zoledronic acid has a strong chemical attraction to bone tissue. Once it reaches bone, it works in two ways: it blocks osteoclasts from maturing in the first place, and it triggers the self-destruction of osteoclasts that are already active. This dramatically slows bone loss and gives the rebuilding process a chance to catch up. Because the drug binds directly into the bone mineral, its effects persist long after the infusion day, which is why a single dose lasts a full year.
How Well It Prevents Fractures
Clinical trials show Reclast reduces the risk of spinal fractures by 46% to 77%, hip fractures by 30% to 41%, and fractures at other sites by 25% to 27%. Those are substantial reductions, particularly for spinal fractures, which are the most common type in people with osteoporosis and can cause chronic pain, loss of height, and a stooped posture.
What Happens on Infusion Day
The standard dose is 5 mg, delivered intravenously over no less than 15 minutes. You’ll sit in a chair with an IV line in your arm, similar to having blood drawn but with fluid flowing in rather than out. The process is quick compared to many other infusion treatments.
Before the infusion, you’ll need to drink at least two glasses of water within a few hours of your appointment. Proper hydration helps protect your kidneys as they process the medication. Your doctor will also want to make sure your calcium and vitamin D levels are adequate beforehand, since the drug can temporarily lower blood calcium. Postmenopausal women are typically advised to take 1,200 mg of calcium and 400 to 800 IU of vitamin D daily if their diet falls short.
For Paget’s disease, the requirements are higher: 1,500 mg of calcium daily (split into two or three doses) and 800 IU of vitamin D, especially in the two weeks after the infusion. Any pre-existing calcium imbalances or mineral metabolism problems need to be corrected before treatment begins.
Common Side Effects After the Infusion
The most talked-about side effect is what doctors call an “acute phase reaction,” essentially a short bout of flu-like symptoms. This can include fever, muscle aches, joint pain, headache, chills, and general fatigue. These symptoms typically appear within the first 24 hours. Fever tends to peak around 24 hours after the infusion, then gradually fades back to normal over about 72 hours. Most people feel completely back to normal within one to three days of symptoms starting.
This reaction is most common after the first infusion and tends to be milder or absent with subsequent yearly doses. Over-the-counter pain relievers can help manage the discomfort. It’s worth planning your infusion for a day when you can take it easy the following day, just in case.
Rare but Serious Risks
Two rare complications are associated with long-term bisphosphonate use, including Reclast.
The first is osteonecrosis of the jaw, a condition where a patch of jawbone loses its blood supply and the overlying gum tissue doesn’t heal. This is defined as exposed bone in the jaw lasting at least eight weeks. The risk is considerably higher in cancer patients receiving more frequent, higher doses of zoledronic acid (roughly 1% after one year, rising to 3% after three years in that population). For osteoporosis patients receiving just one infusion per year, the risk is much lower, though dental health should still be maintained.
The second is atypical femur fractures, unusual breaks in the thighbone that can occur with minimal trauma after prolonged bisphosphonate use. These are extremely rare but are one reason doctors periodically reassess whether to continue treatment after several years.
Who Should Not Get Reclast
Reclast is not appropriate for people with significant kidney impairment, low blood calcium levels that haven’t been corrected, or known allergies to zoledronic acid. If you have kidney concerns, your doctor will check your kidney function with a blood test before approving the infusion. People with conditions that affect mineral absorption, such as those who’ve had parts of their small intestine removed or who have hypoparathyroidism, need those issues managed first.
Where Reclast Fits in Treatment
For many people, Reclast is appealing because of its once-yearly dosing. Oral bisphosphonates like alendronate require weekly or daily pills taken on an empty stomach while sitting upright for 30 minutes, which some people find difficult to stick with. Reclast eliminates adherence issues entirely: one infusion, and you’re covered for the year.
Reclast also plays an important role as a follow-up treatment. When patients finish a course of bone-building medications (which actively stimulate new bone formation rather than just slowing loss), guidelines recommend transitioning to Reclast or another bisphosphonate to lock in the gains. It’s also the recommended option when patients stop denosumab, another osteoporosis drug that can cause rapid bone loss if discontinued without a bridging treatment.